carvedilol has been researched along with Lung Adenocarcinoma in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "However, she experienced recurrence with positive T790 M, and osimertinib (80 mg/day) was administered as the 2nd line therapy." | 1.56 | Osimertinib induced cardiomyopathy: A case report. ( Ishikawa, K; Kagamu, H; Kaira, K; Shinomiya, S; Yamaguchi, O, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shinomiya, S | 1 |
| Kaira, K | 1 |
| Yamaguchi, O | 1 |
| Ishikawa, K | 1 |
| Kagamu, H | 1 |
1 other study available for carvedilol and Lung Adenocarcinoma
| Article | Year |
|---|---|
Osimertinib induced cardiomyopathy: A case report.
Topics: Acrylamides; Adenocarcinoma of Lung; Adrenergic beta-Antagonists; Afatinib; Aged; Angiotensin-Conver | 2020 |